Psoriasis Drug Market ~5B by 2017Research report available outlines that Psoriasis market will almost double to ~5B by 2017.
https://www.decisionresources.com/press_releases/pr_12_02_08.htm
Based upon more acceptance of Biologics but at what cost, I read that Stelara (ustekinumab) would be taken 4 times per year at a cost of $2,000 per injection and compete with the likes of the other Biologics like Humira.
Still there are the long-term safety concerns of the TNF brands and the unknown long-term safety of the interleukin types. For example, the trial with Stelera vs Enbrel had ~ 900 patients but was a 3 month trial, so questions about long-term from FDA and professionals.
So in a ~5B potential market, why can there not be room for other drug options like Voclosporin that could provide a lower cost, good safety/efficacy profile, convenience factor, better appeal to drug plans/government etc?.
The report identifies 3 x Phase 3 drugs, and Isotechnica is one of the companies in the report.